Key result
Highest myocardial contraction fraction tertile is linked to ~74% lower all-cause mortality in HCM.
Why the study?
The study was conducted to evaluate whether myocardial contraction fraction could predict adverse outcomes in patients with hypertrophic cardiomyopathy.
Does higher myocardial contraction fraction (MCF) predict lower mortality in patients with hypertrophic cardiomyopathy?
Cohort (n=438)
No
Does higher myocardial contraction fraction (MCF) predict lower mortality in patients with hypertrophic cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Myocardial contraction fraction (MCF) is a strong, independent predictor of all-cause and HCM-related mortality in patients with hypertrophic cardiomyopathy, offering a useful noninvasive echocardiographic tool for risk stratification.
The myocardial contraction fraction (MCF: stroke volume to myocardial volume) is a novel volumetric measure of left ventricular myocardial shortening. The purpose of the present study was to assess whether MCF could predict adverse outcomes for HCM patients. A retrospective cohort study of 438 HCM patients was conducted. The primary and secondary endpoints were all-cause mortality and HCM-related mortality. The association between MCF and endpoints was analysed. During a follow-up period of 1738.2 person-year, 76 patients (17.2%) reached primary endpoint and 50 patients (65.8%) reached secondary endpoint. Both all-cause mortality rate and HCM-related mortality rate decreased across MCF tertiles (24.7% vs. 17.9% vs. 9.5%, P trend = 0.003 for all-cause mortality; 16.4% vs. 9.7% vs. 6.1%, P trend = 0.021 for HCM-related mortality). Patients in the third tertile had a significantly lower risk of developing adverse outcomes than patients in the first tertile: all-cause mortality (adjusted HR: 0.26, 95% CI: 0.12-0.56, P = 0.001), HCM-related mortality (adjusted HR: 0.17, 95% CI: 0.07-0.42, P < 0.001). At 1-, 3-, and 5-year of follow-up, areas under curve were 0.699, 0.643, 0.618 for all-cause mortality and 0.749, 0.661, 0.613 for HCM-related mortality (all P value < 0.001), respectively. In HCM patients, MCF could independently predict all-cause mortality and HCM-related mortality, which should be considered for overall risk assessment in clinical practice.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2020) conducted a cohort in Hypertrophic cardiomyopathy (n=438). Highest tertile of myocardial contraction fraction (MCF) vs. Lowest tertile of MCF was evaluated on All-cause mortality (HR 0.26, 95% CI 0.12-0.56, p=0.001). In patients with hypertrophic cardiomyopathy, being in the highest tertile of myocardial contraction fraction reduced the risk of all-cause mortality compared to the lowest tertile.
Synapse has enriched 10 related papers. Consider them for comparative context: